Pharmaceutical

FDA removes safety programme for CAR-T therapies to boost uptake

The agency stated that REMS requirements can be removed because safety and effectiveness are assured without them.

Jul 1, 2025 - 06:01
FDA removes safety programme for CAR-T therapies to boost uptake
The agency stated that REMS requirements can be removed because safety and effectiveness are assured without them.
Read the original article

Tags:

Previous Article

CKD anemia market expected to reach $5.3bn across the 7MM by 2034

Next Article

Sobi gains FDA approval for Gamifant to treat HLH/MAS

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more

STAT+: Pharmalittle: We’re reading about a nixed Medica...

Mar 4, 2024

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag

MSD ventures into fibroblast therapies with $1.9bn deal...

Oct 10, 2024

Exelixis focuses on future growth despite COSMIC-313 trial challenges

Exelixis focuses on future growth despite COSMIC-313 tr...

Mar 1, 2025